Skip to main content
Erschienen in: Journal für Gynäkologische Endokrinologie/Schweiz 3/2022

13.09.2022 | Prävention

Die individualisierte Prävention des Mammakarzinoms

verfasst von: Dr. med. Constanze Elfgen

Erschienen in: Journal für Gynäkologische Endokrinologie/Schweiz | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Über die häufigste Krebserkrankung der Frau, das Mammakarzinom, sind heute multiple beinflussbare und nichtbeeinflussbare Risikofaktoren bekannt. Es ist entscheidend, das individuelle Risiko zu kennen, um durch gezielte Massnahmen ebensolches senken zu können. Dieser Übersichtsartikel zeigt die Gewichtung der einzelnen Risikofaktoren als Basis für eine Beratung im ärztlichen Alltag. Präventive Massnahmen sind beispielsweise körperliche Aktivität, Gewichtsreduktion und Senkung des Alkoholkonsums. In bestimmten Konstellationen ist eine genetische Testung sinnvoll; bei sehr hohem Risiko, z. B. durch eine pathogene BRCA-Mutation, kommen auch risikoreduzierende Mastektomien infrage.
Literatur
2.
Zurück zum Zitat Katuwal S, Tapanainen J, Pukkala E (2022) Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer. Breast Cancer Res Treat 193:495–505CrossRef Katuwal S, Tapanainen J, Pukkala E (2022) Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer. Breast Cancer Res Treat 193:495–505CrossRef
3.
Zurück zum Zitat Pashayan N et al (2021) Should age-dependent absolute risk thresholds be used for risk stratification in risk-stratified breast cancer screening? J Pers Med 11:916CrossRef Pashayan N et al (2021) Should age-dependent absolute risk thresholds be used for risk stratification in risk-stratified breast cancer screening? J Pers Med 11:916CrossRef
4.
Zurück zum Zitat Brentnall AR, Cuzick J (2020) Risk models for breast cancer and their validation. Stat Sci 35:14–30CrossRef Brentnall AR, Cuzick J (2020) Risk models for breast cancer and their validation. Stat Sci 35:14–30CrossRef
5.
Zurück zum Zitat Van der Kolk DM et al (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 124:643–651CrossRef Van der Kolk DM et al (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 124:643–651CrossRef
6.
Zurück zum Zitat Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C et al (2000) Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 18:119S–124SPubMed Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C et al (2000) Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 18:119S–124SPubMed
8.
Zurück zum Zitat Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055–1062CrossRef Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055–1062CrossRef
9.
Zurück zum Zitat Singer CF (2021) Nonsurgical prevention strategies in BRCA1 and BRCA2 mutation carriers. Breast Care 16:144–148CrossRef Singer CF (2021) Nonsurgical prevention strategies in BRCA1 and BRCA2 mutation carriers. Breast Care 16:144–148CrossRef
10.
Zurück zum Zitat Rageth CJ et al (2019) Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 174:279–296CrossRef Rageth CJ et al (2019) Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 174:279–296CrossRef
11.
Zurück zum Zitat Pettersson A et al (2014) Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 106:dju78CrossRef Pettersson A et al (2014) Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 106:dju78CrossRef
12.
Zurück zum Zitat Shieh Y et al (2019) Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Res 21:48CrossRef Shieh Y et al (2019) Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Res 21:48CrossRef
13.
Zurück zum Zitat Hilakivi-Clarke L (2014) Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters. Breast Cancer Res 16:208CrossRef Hilakivi-Clarke L (2014) Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters. Breast Cancer Res 16:208CrossRef
14.
Zurück zum Zitat Schaapveld M et al (2015) Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 373:2499–2511CrossRef Schaapveld M et al (2015) Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 373:2499–2511CrossRef
15.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13:1141–1151CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13:1141–1151CrossRef
16.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159–1168CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159–1168CrossRef
17.
Zurück zum Zitat Stute P (2019) Und eine HRT „macht“ doch Brustkrebs!? Gynäkol Endokrinol 17:284–287CrossRef Stute P (2019) Und eine HRT „macht“ doch Brustkrebs!? Gynäkol Endokrinol 17:284–287CrossRef
18.
Zurück zum Zitat Munsell MF et al (2014) Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 36:114–136CrossRef Munsell MF et al (2014) Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 36:114–136CrossRef
19.
Zurück zum Zitat Kawai M et al (2014) Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. Cancer 120:1026–1034CrossRef Kawai M et al (2014) Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. Cancer 120:1026–1034CrossRef
20.
Zurück zum Zitat LoConte NK et al (2018) Alcohol and cancer: a statement of the American Society of Clinical Oncology. J Clin Oncol 36:83–93CrossRef LoConte NK et al (2018) Alcohol and cancer: a statement of the American Society of Clinical Oncology. J Clin Oncol 36:83–93CrossRef
21.
Zurück zum Zitat Endogenous Hormones and Breast Cancer Collaborative Group (2011) Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105:709–722CrossRef Endogenous Hormones and Breast Cancer Collaborative Group (2011) Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105:709–722CrossRef
22.
Zurück zum Zitat Mocellin S et al (2019) Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev 4:CD12191PubMed Mocellin S et al (2019) Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev 4:CD12191PubMed
23.
Zurück zum Zitat Chen L et al (2019) Milk and yogurt intake and breast cancer risk: a meta-analysis. Medicine 98:e14900CrossRef Chen L et al (2019) Milk and yogurt intake and breast cancer risk: a meta-analysis. Medicine 98:e14900CrossRef
24.
Zurück zum Zitat Fraser GE et al (2020) Dairy, soy, and risk of breast cancer: those confounded milks. Int J Epidemiol 49:1526–1537CrossRef Fraser GE et al (2020) Dairy, soy, and risk of breast cancer: those confounded milks. Int J Epidemiol 49:1526–1537CrossRef
25.
Zurück zum Zitat Pizot C et al (1990) Physical activity, hormone replacement therapy and breast cancer risk: a meta-analysis of prospective studies. Eur J Cancer 52:138–154CrossRef Pizot C et al (1990) Physical activity, hormone replacement therapy and breast cancer risk: a meta-analysis of prospective studies. Eur J Cancer 52:138–154CrossRef
26.
Zurück zum Zitat Dite GS et al (2016) Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol 25:359–365 Dite GS et al (2016) Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol 25:359–365
27.
Zurück zum Zitat Tice JA et al (2019) Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat 175:519–523CrossRef Tice JA et al (2019) Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat 175:519–523CrossRef
28.
Zurück zum Zitat Tyrer J et al (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111–1130CrossRef Tyrer J et al (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111–1130CrossRef
29.
Zurück zum Zitat Brown KF et al (2015) The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer 118:1130–1141CrossRef Brown KF et al (2015) The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer 118:1130–1141CrossRef
Metadaten
Titel
Die individualisierte Prävention des Mammakarzinoms
verfasst von
Dr. med. Constanze Elfgen
Publikationsdatum
13.09.2022
Verlag
Springer Vienna
Erschienen in
Journal für Gynäkologische Endokrinologie/Schweiz / Ausgabe 3/2022
Print ISSN: 1995-6924
Elektronische ISSN: 2520-8500
DOI
https://doi.org/10.1007/s41975-022-00260-0

Weitere Artikel der Ausgabe 3/2022

Journal für Gynäkologische Endokrinologie/Schweiz 3/2022 Zur Ausgabe

Editorial

Editorial

Schon gewusst…?

Schon gewusst …?

Der rätselhafte Fall

Zufallsbefund bei Endometriose